What We Do

Successful studies depend on the collective performance of individual sites. RapidTrials optimizes site performance on clinical trials. We help sponsors and sites develop the skills and resources necessary to anticipate and overcome performance obstacles. By improving communication and strengthening the partnership between sponsors and sites, we significantly increase the certainty of study completion on time and within budget.

Most drug and biotech companies have well-established strategies for working with large outsourcing entities such as central labs and CRO’s, yet few have devoted substantial resources to working with sites. For the past decade, RapidTrials has been at the forefront of aiding sponsors in selecting, assessing, and managing sites, with an end result of significantly faster enrollment and more efficient, high-quality trial execution.

Executive Team

Tracy Harmon Blumenfeld – Co-founder, President and Chief Executive Officer

RapidTrials, a pharmaceutical service provider, is a leader in improving the efficiency of clinical trials for drug development firms and medical research sites. The Company’s clients include global biopharmaceutical companies and medical research centers. Under Ms. Blumenfeld’s leadership, RapidTrials has been selected as a member of the Philadelphia 100, a distinction conferred on the 100 fastest growing, privately held companies in the greater Philadelphia region. The Philadelphia 100 program is run by the Wharton Small Business Development Center, the Entrepreneurs’ Forum of Greater Philadelphia, and the Philadelphia Business Journal.

Ms. Blumenfeld has published and contributed to numerous articles on site selection, site performance, and study economics in journals such as Pharmaceutical Executive, the Group Practice Journal of the American Medical Association, and The Monitor, a peer-reviewed journal of the Association of Clinical Research Professionals. She has presented to industry and university researchers at conferences convened by the Drug Information Association, the National Institutes of Health, the Association for the Accreditation of Human Research Protection Programs, Inc., and the Harvard Global Health Institute’s Multi-Regional Clinical Trials (MRCT) Center. She has been a guest lecturer on clinical trials for the joint Brandeis and Tufts University MD/MBA program.

Ms. Blumenfeld is a member of the Board of Directors for the Mental Health Association of Southeastern Pennsylvania, a Co-Chair of the Site Accreditation Standards Initiative Project Steering Committee of the Alliance for Clinical Research Excellence and Safety, a Senior Advisor at the Wharton Small Business Development Center, and a member of the (MRCT) Center.

Prior to founding RapidTrials, Ms. Blumenfeld served as a Principal for the Consulting and Productivity Products Group, at Parexel International, a contract research organization. At Parexel, she was responsible for designing the industry’s first metrics-based approach for comparing R&D efficiency and performance across leading pharmaceutical companies worldwide. Earlier in her career, she worked as the Director of Marketing and in Business Development for RehabClinics a corporate healthcare company that provided physical and occupational rehabilitation services at hundreds of outpatient throughout the US; as an Associate at Booz Allen and Hamilton’s Pharmaceutical Strategy Practice; and as a Senior Consultant in the Baxter Management Services Division at Baxter Healthcare Corporation.

Ms. Blumenfeld has a BA degree in Economics from Northwestern University and a Masters of Business Administration from Harvard Business School.

Wolffe Nadoolman, MD MBA – Medical Director/Co-founder
With experience as a practicing primary care physician as well as a researcher, Dr. Nadoolman has published numerous papers and has been awarded a patent, with others pending. Formerly an executive at Salomon Brothers, he has helped start several companies. As a consultant, he analyzed productivity in clinical trials. Dr. Nadoolman has also just recently founded Private Pediatrics, Inc. in Berkeley, CA. He holds a medical degree from Yale University School of Medicine, a Masters of Business Administration from Harvard Business School and a Bachelors Degree from Cornell University. He is an Expert Medical Reviewer for the Medical Board of the State of California, is a former Institutional Review Board member, and a diplomat of relevant training by the NIH Office of Human Subjects Research and in Bioethics by the Kennedy School of Ethics at Georgetown University. Dr. Nadoolman has worked as a consultant to Pfizer Inc. and has participated in a Pfizer Roundtable, published in The Pfizer Journal, on Healthcare Quality.

Advisory Board

Linda A. Barnes Meyerson, R.Ph
Linda recently retired as the chief operating officer at ICON, a pharmaceutical services company based in Philadelphia where she was responsible for handling clinical operations, conducting clinical trial programs, and analyzing data that support clinical development and clinical study management. She also oversaw all regulatory and safety issues for the firm.  Ms. Meyerson earned a bachelor’s degree in biology from Trenton State College as well as a bachelor’s degree in pharmacy from St. John’s University, and has more than three decades of experience in the health care and pharmaceutical fields. Prior to her current role with ICON, Ms. Meyerson filled a number of key positions with leading companies in the industry, including serving as the vice president of global clinical operations at GlaxoSmithKline. Her responsibilities at GSK  included conceptualizing, designing, and implementing GSK’s operational activities and providing direct leadership for a wide range of line functions, including clinical submissions development, clinical study management, metrics and benchmarking, and field monitors worldwide. Prior to her work at GSK, she held a succession of leadership positions with the Janssen Research Foundation and the RW Johnson Pharmaceutical Research Institute. She is a member of the Biotech & Pharma Professionals Network, and is a member of the advisory board for RapidTrials.

Claude H. Nash, PhD
Claude Nash works with biotechnology company management to establish strategic focus in order to facilitate access to the capital markets. He serves on both private and public company boards. Claude currently serves on the board of directors of Bloodstone Ventures, Adolor, Selectx Pharmaceutical and is the Chairman of Accera.

Before setting up Nash Consulting 2006, Claude served as the President and CEO Bloodstone Ventures plc from 2006 to 2008. Bloodstone’s primary focus is value creation through the commercialization of leading biomedical technologies discovered at universities. Two new start-up companies have now been formed with start-up funding. Prior to joining Bloodstone, Claude served from 2003-2006 as Vice President for Research and Development at University of Maryland Biotechnology Institute where he was responsible for sponsored programs and technology portfolio management. During his tenure six new start-up companies were formed and the sponsored research more than doubled.

Dr. Nash has more than 30 years of pharmaceutical industry experience, which includes advancing more than 20 compounds into clinical trials, five of which are currently approved products. Dr. Nash founded ViroPharma Incorporated in December 1994 and served as the President, CEO and/or Chairman of the board until 2002. He led the company through its initial public offering and raised over $ 450 M of capital through several additional secondary offerings. Prior to ViroPharma, Dr. Nash served as vice president for infectious disease and oncology at Schering Plough Research Institute. Previously, he held various positions with Sterling Drugs, SmithKine Beecham, and Eli Lilly. He received the Charles Porter Award from the Society for Industrial Microbiology and is a member of The American Academy of Microbiology, Phi Kappa Phi, Sigma Xi and Beta, Beta, Beta, Biological honor societies. He holds a Ph. D. and MS degree.

Alan N. Vinick, JD, MBA
Currently the CFO at TMG Health, a Business Process Outsourcing (BPO) service provider to the Medicare, Medicaid and retiree health plan markets Alan N. Vinick is a senior financial executive with an extensive background working with growth-oriented companies. He has served as Chief Financial Officer of five healthcare companies, four of which were sponsored by the same venture capital firm, including Apogee, Inc., RehabClinics, Inc., Orthopedic Services, Inc., Heritage Health Systems, Inc., and John Hancock Health Plans, Inc. and has been involved in two successful IPOs. Earlier in his career, Mr. Vinick was an officer of CIGNA Corporation and Secretary to the Emergency Loan Guarantee Board. He began his career with the U.S. Securities and Exchange Commission. He holds a JD from the Columbus School of Law, an MBA from the University of Massachusetts, and a BS from Babson College.